Mechanistically, exogenous itaconate suppressed NLRP3 inflammasome activation in LCWE-induced cardiovascular lesions and decreased IL-1β secretion.<h4>Conclusions</h4>Itaconate treatment provides cardiovascular protection in an experimental mouse model of KD vasculitis by decreasing NLRP3 inflammasome activation and reducing vascular inflammation. Here, NLRP3 is linked to vasculitis.